Canada Markets closed

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3200-0.0400 (-11.11%)
At close: 3:59PM EST
Full screen
Previous Close0.3600
Open0.3650
Bid0.3200 x N/A
Ask0.3300 x N/A
Day's Range0.3200 - 0.3900
52 Week Range0.1900 - 1.2400
Volume658,499
Avg. Volume458,748
Market Cap21.783M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

    Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening conditions with ketamine TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Or

  • GlobeNewswire

    PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

    Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.Completing microneedle patch research programs with other psychedelics before year-end.Pursuing Phase 2 clinical studies in 2022 with psilocybin and notable psychedelics. TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company,

  • GlobeNewswire

    PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

    Focusing on partnership model for MicroDose-MN™ and MacroDose-MN™ patches to deliver psychedelics.Creating value and intellectual property protection for psychedelic programs.Providing pathways for partners to enter FDA Phase 1 and 2 clinical studies in 2022 with psychedelics. TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce it has entered into a re